-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tau disease refers to the disorder of tau protein aggregation, which is heterogeneous in biochemistry, morphology and clinical manifestations.
Tau disease refers to the disorder of tau protein aggregation, which is heterogeneous in biochemistry, morphology and clinical manifestations.
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind study conducted in 66 hospitals and clinics in multiple countries.
diagnosis
From December 12, 2016 to December 31, 2018, a total of 466 participants were screened and 378 participants were randomly divided into groups.
In this phase 2 study of progressive supranuclear palsy, although Telavirumab was not effective in the treatment of progressive supranuclear palsy, the safety of all treatment groups was similar.
Biomarker analysis showed that Tiranezumab binds to target cells.
Höglinger, Günter UAhmed, Anwar et al.
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
The Lancet Neurology, Volume 20, Issue 3, 182-192 Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
Leave a message here